• Startup Elcelyx Raises $1.2 Million

    Updated: 2010-03-18 19:37:27
    Elcelyx Therapeutics of San Diego has raised $1.2 million of a planned $2.2 million equity offering, according to an SEC filing. The document says the company’s president is Alain D. Baron,... [[Click headline to continue reading.]]

  • Somaxon Shares Boom on FDA Approval for Insomnia Drug

    Updated: 2010-03-18 18:08:50
    After three tries, Somaxon Pharmaceuticals has won FDA approval for its insomnia drug. The San Diego-based biotech company said today it has gotten clearance to start selling doxepin (Silenor) in the... [[Click headline to continue reading.]]

  • Francis Collins announces voluntary genetic test registry [Genetic Future]

    Updated: 2010-03-18 18:00:00
    Now on ScienceBlogs : The animal research experience Last 24 Hrs Life Science Physical Science Environment Humanities Education Politics Medicine Brain Behavior Technology Information Science Jobs Genetic Future Commentary on human genetics and evolution , direct-to-consumer genetic testing , and the personal genomics . industry Latest Posts Archives About Contact Subscribe i Search Profile Daniel MacArthur I write about the genetic and evolutionary basis of human variation , and the companies trying to sell you information about your . genome Subscribe via RSS Follow me on Twitter Recent Posts Francis Collins announces voluntary genetic test registry Willful ignorance is not an effective argument against personal genomics On plausible alternative hypotheses Celebrity genomics without the Y chromosome : Glenn Close has her genome sequenced Disease hunting with whole genome sequences : the good news , and the bad news State of sequencing technology in 2010 Genetic ancestry testing : people who don't want to know On finding folks you know : 23andMe reveals some unexpected cousins The end is nigh for 23andMe New players in sequencing debut at AGBT Recent Comments Andrew Yates on

  • Intern – Antibody Engineering – Biogen Idec – San Diego, CA

    Updated: 2010-03-18 14:01:21
    ideal candidate will be pursuing a degree in molecular biology, biochemistry, biotechnology or biological sciences. The intern will gain experience in antibody... From Biogen Idec - 18 Mar 2010 14:01:21 GMT - job details - View all San Diego jobs

  • Sequenom Speaks Out, Amylin Receives a Setback, Somaxon Awaits FDA Decision, & More San Diego Life Sciences News

    Updated: 2010-03-18 08:40:28
    Regulatory news dominated the headlines in the past week. We have it summarized for you here. —Sequenom (NASDAQ: SQMN) said a lack of adequate controls, protocols and supervision were to blame... [[Click headline to continue reading.]]

  • Abraxis Looks Promising in Lung Cancer War (ABII)

    Updated: 2010-03-17 23:24:07
    Submitted by BioHealth Investor Blog Abraxis BioScience, Inc. (NASDAQ: ABII) is one of the top biotech gainers this morning.  The company announced that its key ABRAXANE met the primary endpoint in a Phase 3 trial for advanced non-small cell lung cancer. The company’s randomized Phase 3 clinical trial comparing ABRAXANE, the company’s protein-bound paclitaxel, along with with [...]

  • StemCells Scores New Stem Cell Patent (STEM)

    Updated: 2010-03-17 23:23:12
    Submitted by BioHealth Investor Blog StemCells, Inc. (NASDAQ: STEM) has a new stem cell patent.  For rats, issued in the United Kingdom.  The company issued a release showing that the United Kingdom Intellectual Property Office granted patent number GB2451523. The patent has broad claims covering true rat stem cells and genetically engineered rats derived from these cells, [...]

  • Stem Cells Versus Aging, Fountain of Youth (BTIM, GERN, ACTC)

    Updated: 2010-03-17 23:22:20
    Submitted by BioHealth Investor Blog How many movies and legends are based upon eternal youth?  Hundreds or thousands for sure.  BioTime, Inc. (NYSE Amex: BTIM) is seeing a massive surge of interest today after the company announced a “Peer-Reviewed Scientific Publication on the Reversal of the Developmental Aging of Normal Human Cells.” The company is a small-cap [...]

  • Sequenom Still Seeks Down’s Syndrome Grail (SQNM)

    Updated: 2010-03-16 01:57:53
    Submitted by BioHealth Investor Blog Sequenom, Inc. (NASDAQ: SQNM) is trading lower in the after-hours session after the troubled diagnostics company reported its year-end earnings.  Because of its recent woes of 2009, the earnings and revenue reports are a true side-show compared to what the company is updating over its pipeline and over its products. We would [...]

  • The Changing Landscape of Biotech Valuations (ACOR, CBST, MNKD, INCY, SGEN, ITMN, IPXL, MRX, SVNT, VPHM)

    Updated: 2010-03-10 02:07:55
    Submitted by BioHealth Investor Blog The biotech and biohealth universe is changing in size.  In 2008 and 2009, partly due to mergers and partly due to market valuations, there had become a surprisingly small number of biotech stocks which had market capitalization rates of more than $1 billion.  At one point there were only about 10 [...]

  • Talking Biotech ETFs: iShares Nasdaq Biochnology to $100 (IBB, OSIP, MDVN)

    Updated: 2010-03-06 00:48:35
    Submitted by BioHealth Investor Blog Today’s price moves in the biotech sector are quite different from what we saw earlier this week.  A hostile merger via tender from Astellas for OSI Pharmaceuticals Inc. (NASDAQ: OSIP) got everyone up in arms this week.  So much that other investors were going back over buyout candidate notes.  We also [...]

  • Biotech Implosion: Medivation, Alzheimer’s Beats Drug (MDVN, PFE)

    Updated: 2010-03-06 00:47:37
    Submitted by BioHealth Investor Blog Medivation, Inc. (NASDAQ: MDVN) is the next biotech implosion.  The company’s highly awaited Phase III study on its Alzheimer drug called Dimebon did not meet expectations. It failed to meet primary and secondary endpoints. The problem is that this was hitting 52-week highs yesterday. The company did note that a separate Phase [...]

  • More Biotech Buyout or M&A Targets (OSIP, VRTX, AUXL, ITMN, HGSI, CELG, DNDN, ENZN, FACT, PBE, XBI)

    Updated: 2010-03-03 02:12:37
    Submitted by BioHealth Investor Blog After today’s hostile Astellas offer for OSI Pharmaceuticals (NASDAQ: OSIP), we have investors and traders alike looking for ‘the next takeover target’ in biotech.  Buy now you know that there are many pitfalls in simply looking for biotech stocks to buy because they will be taken over.  We have taken a [...]

  • Hostile Mergers Back in Biotech (OSIP)

    Updated: 2010-03-03 02:07:01
    Submitted by BioHealth Investor Blog Mergers are back in biotech…. Astellas Pharma Inc., a global pharmaceutical company in Japan, announced that it will commence a tender offer to acquire all outstanding shares of common stock of OSI Pharmaceuticals (NASDAQ: OSIP).  The direct tender is nothing short of a hostile merger after Astellas said that OSI has [...]

  • Generic Drug Wars… Is Dr. Reddy’s The Answer? (RDY, TEVA, GSK)

    Updated: 2010-03-01 01:22:42
    Submitted by BioHealth Investor Blog Generic drugs are just one of the many combined issues that are coming front and center in the world of healthcare reform.   Frankly this is not a new notion.  Not all.  This weekend came a feature in Barron’s “Asian Trader: Pill Maker That’s Set To Pop” calling Dr. Reddy’s Laboratories Ltd. [...]

  • Sackler Brothers Ties to Purdue Pharma and Profits

    Updated: 2010-02-27 21:23:34
    Submitted by PharmaGossip   via salem-news.com Pic - Richard Sackler, co-chairman of Stamford, Connecticut based Purdue Pharma and adjunct professor of genetics at Rockefeller University. Visit 1800blogger to see all of our industry leading blogs.

  • PharmedOut Conference: June 25th 2010

    Updated: 2010-02-27 16:25:01
    Submitted by PharmaGossip PharmedOut is pleased to announce a conference. “Prescription for Conflict: Should Industry Fund Continuing Medical Education?” will be held on Friday, June 25, 2010, on the Georgetown campus in Washington DC. We intend to address the questions: Does drug industry funding of CME adversely affect the educational content of CME? If so, can commercial [...]

  • Pfizer - Rapamune: DOJ conducts criminal probe

    Updated: 2010-02-27 03:27:01
    Submitted by PharmaGossip Federal prosecutors in Oklahoma are conducting a criminal investigation of a Pfizer unit’s promotional practices for organ-transplant drug Rapamune, the drug maker disclosed Friday. New York-based Pfizer said in a regulatory filing the U.S. Attorney’s office for the western district of Oklahoma was conducting the probe. There were no further details in the regulatory [...]

  • Life’s smallest motor, cargo carrier of the cells, moves like a seesaw

    Updated: 2010-02-19 15:37:49
    Life’s smallest motor, a protein that shuttles cargo within cells and helps cells divide, does so by rocking up and down like a seesaw, according to research conducted by scientists at the U.S. Department of Energy’s Lawrence Berkeley National Laboratory and Brandeis University. The researchers created high-resolution snapshots of a protein motor, called kinesin, as it [...] (Source: Biosingularity)

Current Feed Items | Previous Months Items

Feb 2010 | Jan 2010 | Dec 2009 | Nov 2009 | Oct 2009 | Sep 2009